Effect of different statins and EZETIMIBE/SIMVASTATIN on cardiovascular disease in patients with chronic kidney disease

Objective To explore the effect of different statins and EZETIMIBE/SIMVASTATIN on cardiovascular disease in patients with chronic kidney disease(CKD). Methods This study was a prospective study design and selected 503 cases of 3-5 phase CKD patients. The subjects were divided into simvastatin group,...

Full description

Saved in:
Bibliographic Details
Main Authors: ZHANG Xue-qing, Yiming·Muyesaier, Abualiti·Alimire, LU Chen
Format: Article
Language:zho
Published: Editorial Department of Journal of Clinical Nephrology 2018-01-01
Series:Linchuang shenzangbing zazhi
Subjects:
Online Access:http://www.lcszb.com/thesisDetails?columnId=57915013&Fpath=home&index=0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849323503080177664
author ZHANG Xue-qing
Yiming·Muyesaier
Abualiti·Alimire
LU Chen
author_facet ZHANG Xue-qing
Yiming·Muyesaier
Abualiti·Alimire
LU Chen
author_sort ZHANG Xue-qing
collection DOAJ
description Objective To explore the effect of different statins and EZETIMIBE/SIMVASTATIN on cardiovascular disease in patients with chronic kidney disease(CKD). Methods This study was a prospective study design and selected 503 cases of 3-5 phase CKD patients. The subjects were divided into simvastatin group,rosuvastatin group,atorvastatin group and EZETIMIBE/SIMVASTATIN group according to their medication history. The end of the event is the occurrence of cardiovascular disease. The Kaplan Meier model was used to verify the effect of the drugs on cardiovascular disease in patients with CKD. Results A total of 435 patients were followed up(104 in the simvastatin group,116 in the rosuvastatin group,112 in the atorvastatin group and 103 in the EZETIMIBE/SIMVASTATIN group). During the follow-up period,the incidence of cardiovascular disease in the four groups was 34. 9 %,33. 9 %,33. 3 % and 25. 4 %,respectively. Compared with the simvastatin group,the probability of cardiovascular disease in rosuvastatin and atorvastatin groups did not decrease significantly(with simvastatin as the reference,the HR of rosuvastatin group was 0. 98,95 % CI 0. 90-1. 04,P = 0. 10,and the HR of atorvastatin group was 0. 97,95 % CI 0.91-1. 04,P = 0. 30). The incidence of cardiovascular disease was significantly lower in EZETIMI-BE/SIMVASTATIN group than that in the rest groups(HR = 0. 59,95 % CI 0. 39-0. 76,P = 0.002). Conclusions Patients with chronic kidney disease treated with EZETIMIBE/SIMVASTATIN can obtain more satisfactory effects than other statins in reducing the incidence of cardiovascular diseases.
format Article
id doaj-art-9ed974cbc0cb496b8524ef023d97697d
institution Kabale University
issn 1671-2390
language zho
publishDate 2018-01-01
publisher Editorial Department of Journal of Clinical Nephrology
record_format Article
series Linchuang shenzangbing zazhi
spelling doaj-art-9ed974cbc0cb496b8524ef023d97697d2025-08-20T03:49:02ZzhoEditorial Department of Journal of Clinical NephrologyLinchuang shenzangbing zazhi1671-23902018-01-0139940457915013Effect of different statins and EZETIMIBE/SIMVASTATIN on cardiovascular disease in patients with chronic kidney diseaseZHANG Xue-qingYiming·MuyesaierAbualiti·AlimireLU ChenObjective To explore the effect of different statins and EZETIMIBE/SIMVASTATIN on cardiovascular disease in patients with chronic kidney disease(CKD). Methods This study was a prospective study design and selected 503 cases of 3-5 phase CKD patients. The subjects were divided into simvastatin group,rosuvastatin group,atorvastatin group and EZETIMIBE/SIMVASTATIN group according to their medication history. The end of the event is the occurrence of cardiovascular disease. The Kaplan Meier model was used to verify the effect of the drugs on cardiovascular disease in patients with CKD. Results A total of 435 patients were followed up(104 in the simvastatin group,116 in the rosuvastatin group,112 in the atorvastatin group and 103 in the EZETIMIBE/SIMVASTATIN group). During the follow-up period,the incidence of cardiovascular disease in the four groups was 34. 9 %,33. 9 %,33. 3 % and 25. 4 %,respectively. Compared with the simvastatin group,the probability of cardiovascular disease in rosuvastatin and atorvastatin groups did not decrease significantly(with simvastatin as the reference,the HR of rosuvastatin group was 0. 98,95 % CI 0. 90-1. 04,P = 0. 10,and the HR of atorvastatin group was 0. 97,95 % CI 0.91-1. 04,P = 0. 30). The incidence of cardiovascular disease was significantly lower in EZETIMI-BE/SIMVASTATIN group than that in the rest groups(HR = 0. 59,95 % CI 0. 39-0. 76,P = 0.002). Conclusions Patients with chronic kidney disease treated with EZETIMIBE/SIMVASTATIN can obtain more satisfactory effects than other statins in reducing the incidence of cardiovascular diseases.http://www.lcszb.com/thesisDetails?columnId=57915013&Fpath=home&index=0Chronic kidney diseaseStatinsEZETIMIBE/SIMVASTATINCardiovascular disease
spellingShingle ZHANG Xue-qing
Yiming·Muyesaier
Abualiti·Alimire
LU Chen
Effect of different statins and EZETIMIBE/SIMVASTATIN on cardiovascular disease in patients with chronic kidney disease
Linchuang shenzangbing zazhi
Chronic kidney disease
Statins
EZETIMIBE/SIMVASTATIN
Cardiovascular disease
title Effect of different statins and EZETIMIBE/SIMVASTATIN on cardiovascular disease in patients with chronic kidney disease
title_full Effect of different statins and EZETIMIBE/SIMVASTATIN on cardiovascular disease in patients with chronic kidney disease
title_fullStr Effect of different statins and EZETIMIBE/SIMVASTATIN on cardiovascular disease in patients with chronic kidney disease
title_full_unstemmed Effect of different statins and EZETIMIBE/SIMVASTATIN on cardiovascular disease in patients with chronic kidney disease
title_short Effect of different statins and EZETIMIBE/SIMVASTATIN on cardiovascular disease in patients with chronic kidney disease
title_sort effect of different statins and ezetimibe simvastatin on cardiovascular disease in patients with chronic kidney disease
topic Chronic kidney disease
Statins
EZETIMIBE/SIMVASTATIN
Cardiovascular disease
url http://www.lcszb.com/thesisDetails?columnId=57915013&Fpath=home&index=0
work_keys_str_mv AT zhangxueqing effectofdifferentstatinsandezetimibesimvastatinoncardiovasculardiseaseinpatientswithchronickidneydisease
AT yimingmuyesaier effectofdifferentstatinsandezetimibesimvastatinoncardiovasculardiseaseinpatientswithchronickidneydisease
AT abualitialimire effectofdifferentstatinsandezetimibesimvastatinoncardiovasculardiseaseinpatientswithchronickidneydisease
AT luchen effectofdifferentstatinsandezetimibesimvastatinoncardiovasculardiseaseinpatientswithchronickidneydisease